Ascentage Pharma Group International (AAPG) Revenue History
Annual and quarterly revenue from 2016 to present
AAPG Revenue Over Time (2016–2025)
AAPG Revenue Growth History
6 of 9 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- -17.5%
- FY2018 revenue growth
- +7.6%
- FY2019 revenue growth
- +113.2%
- FY2020 revenue growth
- -14.2%
- FY2021 revenue growth
- +124.2%
- FY2022 revenue growth
- +651.4%
- FY2023 revenue growth
- +5.9%
- FY2024 revenue growth
- +341.8%
- FY2025 revenue growth
- -43.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $298.9M | +27.9% |
| Q4 2025 | $334.1M | +113.0% |
| Q2 2025 | $233.7M | -71.6% |
| Q4 2024 | $156.9M | +97.9% |
| Q2 2024 | $823.7M | +477.3% |
| Q4 2023 | $79.3M | -24.4% |
| Q2 2023 | $142.7M | +36.1% |
| Q4 2022 | $104.9M | +601.6% |
AAPG Revenue Analysis (2016–2025)
Current Revenue & Growth
As of October 3, 2026, Ascentage Pharma Group International (AAPG) generated trailing twelve-month (TTM) revenue of $1.02 billion, reflecting exceptional growth of +27.9% year-over-year. The most recent quarter (Q2 2026) recorded $298.9 million in revenue, down 10.6% sequentially.
Historical Growth Trajectory
AAPG's 5-year compound annual growth rate (CAGR) stands at +114.0%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +38.6% is below the 5-year average, signalling a growth deceleration in recent years. Ascentage Pharma Group International's highest annual revenue of $980.6 million was recorded in 2024.
Peer Comparison
Compared to Healthcare sector peers — including ABBV (+10.4% YoY), BCAB (-22.7% YoY), and KYMR (+134.8% YoY) — AAPG has outperformed the peer group in revenue growth. Compare AAPG vs ABBV →
AAPG Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AAPGCurrent | $1.0B | +27.9% | +114.0% | -211.1% | |
 ABBV | $61.2B | +10.4% | +6.0% | 32.8% | |
 BCAB | $2M | -22.7% | +36.1% | -2965.3% | |
 KYMR | $39M | +134.8% | +2.9% | -891.3% | |
 ARVN | $263M | -15.0% | +58.9% | -43.8% |
AAPG Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $558.5M | -43.1% | $426.7M | 76.4% | $-1,179,161,166 | -211.1% |
| 2024 | $980.6M | +341.8% | $951.6M | 97.0% | $-369,730,000 | -37.7% |
| 2023 | $222.0M | +5.9% | $191.4M | 86.2% | $-872,636,000 | -393.1% |
| 2022 | $209.7M | +651.4% | $187.7M | 89.5% | $-849,810,000 | -405.2% |
| 2021 | $27.9M | +124.2% | $24.6M | 88.1% | $-869,835,000 | -3116.6% |
| 2020 | $12.4M | -14.2% | $10.5M | 84.2% | $-663,941,000 | -5332.9% |
| 2019 | $14.5M | +113.2% | $12.4M | 85.6% | $-582,685,000 | -4014.9% |
| 2018 | $6.8M | +7.6% | $6.8M | 100.0% | $-345,443,612 | -5074.8% |
| 2017 | $6.3M | -17.5% | $6.3M | 100.0% | $-130,668,000 | -2064.9% |
| 2016 | $7.7M | - | $7.4M | 96.6% | $-114,622,000 | -1495.0% |
AAPG Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AAPG — Frequently Asked Questions
Quick answers to the most common questions about buying AAPG stock.
Is AAPG's revenue growth accelerating or slowing?
AAPG revenue growth is accelerating. TTM revenue reached $1.0B, up +27.9% year-over-year — ahead of the 5-year CAGR of +114.0%. This indicates the business is expanding faster than its historical baseline.
What is AAPG's revenue history from 2016 to 2026?
Ascentage Pharma Group International (AAPG) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $1.0B, growing at +27.9% YoY. The 5-year CAGR is +114.0%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is AAPG's long-term revenue growth rate (CAGR)?
Ascentage Pharma Group International's 5-year revenue CAGR of +114.0% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +27.9% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for AAPG.
Why does AAPG's quarterly revenue fluctuate?
AAPG quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Ascentage Pharma Group International's revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is AAPG's revenue distributed by segment?
AAPG reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does AAPG's revenue compare to industry peers?
Ascentage Pharma Group International (AAPG) with TTM revenue of $1.0B and +27.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.